- Home
- PLCE vs CRBP Comparison
PLCE vs CRBP Comparison
Compare PLCE & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PLCE
- CRBP
- Stock Information
- Founded
- PLCE 1969
- CRBP 2009
- Country
- PLCE United States
- CRBP United States
- Employees
- PLCE N/A
- CRBP N/A
- Industry
- PLCE Clothing/Shoe/Accessory Stores
- CRBP Biotechnology: Pharmaceutical Preparations
- Sector
- PLCE Consumer Discretionary
- CRBP Health Care
- Exchange
- PLCE Nasdaq
- CRBP Nasdaq
- Market Cap
- PLCE 76.8M
- CRBP 73.4M
- IPO Year
- PLCE 1997
- CRBP N/A
- Fundamental
- Price
- PLCE $5.71
- CRBP $6.45
- Analyst Decision
- PLCE Hold
- CRBP Strong Buy
- Analyst Count
- PLCE 2
- CRBP 10
- Target Price
- PLCE $9.00
- CRBP $53.56
- AVG Volume (30 Days)
- PLCE 601.6K
- CRBP 147.8K
- Earning Date
- PLCE 06-11-2025
- CRBP 05-06-2025
- Dividend Yield
- PLCE N/A
- CRBP N/A
- EPS Growth
- PLCE N/A
- CRBP N/A
- EPS
- PLCE N/A
- CRBP N/A
- Revenue
- PLCE $1,386,269,000.00
- CRBP N/A
- Revenue This Year
- PLCE N/A
- CRBP N/A
- Revenue Next Year
- PLCE N/A
- CRBP $150.00
- P/E Ratio
- PLCE N/A
- CRBP N/A
- Revenue Growth
- PLCE N/A
- CRBP N/A
- 52 Week Low
- PLCE $4.77
- CRBP $4.64
- 52 Week High
- PLCE $19.74
- CRBP $61.90
- Technical
- Relative Strength Index (RSI)
- PLCE 45.68
- CRBP 46.87
- Support Level
- PLCE $4.81
- CRBP $6.10
- Resistance Level
- PLCE $6.00
- CRBP $8.07
- Average True Range (ATR)
- PLCE 0.48
- CRBP 0.71
- MACD
- PLCE 0.17
- CRBP -0.10
- Stochastic Oscillator
- PLCE 57.32
- CRBP 13.31
About PLCE Children's Place Inc. (The)
Children's Place Inc operate an omni-channel children's specialty portfolio of brands in North America. It design, contract to manufacture, and sell fashionable, high-quality apparel, accessories and footwear predominantly at value prices under proprietary The Children's Place, Place, Baby Place, Gymboree, Sugar & Jade, and PJ Place brand names.
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.